Free Trial

Novo Nordisk Q2 Slightly Soft Albeit With Guidance Raise; Withdraws Wegovy Submission

HEALTHCARE

Rating: A1[P]/AA-

  • “*NOVO 2Q SALES DKK68.06B, EST. DKK68.72B
  • *NOVO 2Q GROSS MARGIN 84.9%, EST. 84.9%
  • *NOVO 2Q EBIT DKK25.93B, EST. DKK27.36B
  • *NOVO 2Q NET INCOME DKK20.05B, EST. DKK22.64B” -BBG

  • “*Novo Nordisk Raises FY Sales Guidance” -DJ
  • “*NOVO SEES FY SALES AT CONSTANT FX +22% TO +28%, EST. +26.8%
  • *NOVO SEES FY OP PROFIT AT CONSTANT FX +20% TO +28%, EST. +25.8%

  • *NOVO WITHDRAWS SUBMISSION TO US FDA ON WEGOVY STEP TRIAL” -BBG

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.